Zobrazeno 1 - 2
of 2
pro vyhledávání: '"David C Sjostrom"'
Autor:
David C. Wheeler, Hiddo J.L. Heerspink, Fan Fan Hou, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Robert D. Toto, Ricardo Correa-Rotter, Peter Rossing, Niels Jong, David C Sjostrom, Bergur V. Stefánsson
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Reductions in albuminuria are consistently associated with a subsequent lower risk of kidney failure. The sodium glucose co-transporter 2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e685954bb73404630a6546f292d95d16
https://doi.org/10.1093/ndt/gfab136.002
https://doi.org/10.1093/ndt/gfab136.002
Autor:
Michelle J Pena, David C. Wheeler, David C Sjostrom, Bergur V. Stefánsson, Hiddo J.L. Heerspink, Nienke M. A. Idzerda
Publikováno v:
Nephrology, Dialysis, Transplantation, 35(9):gfz064, 1570-1576. Oxford University Press
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation
Background Besides improving glucose control, sodium-glucose co-transporter 2 inhibition with dapagliflozin reduces blood pressure, body weight and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes (T2DM). The parameter respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1d6d92b7ee9965e17a0d9ab44cfd1ab
https://research.rug.nl/en/publications/3c230131-e6d9-48b3-8e4d-cb9d61467a72
https://research.rug.nl/en/publications/3c230131-e6d9-48b3-8e4d-cb9d61467a72
